Pfizer Inc., AstraZeneca, and Kowa Pharmaceuticals America Inc. were dominating the U.S. Statin Market in 2021

U.S. Statin Market is expected to grow with the CAGR of 1.5% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/us-statin-market

U.S. statin market has witnessed increased strategic developments owing to favourable market scenario.    

The major players dealing in the U.S. statin market are introducing strong range of products and adopting strategic initiative such as acquisition, agreement, new product launches into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance-

  • In April 2017, Teva Pharmaceutical Industries Ltd. announced the launch of generic Vytorin1 (ezetimibe and simvastatin) tablets in the U.S. Ezetimibe and simvastatin tablets are a prescription medicine that contains two cholesterol lowering medicines, ezetimibe and simvastatin, which are used along with diet. This benefitted the consumers.

Pfizer Inc. is the dominating player in U.S. statin market. The other key players existing in the market includes Merck KGaA, Kowa Pharmaceuticals America, Inc., Dr. Reddy’s Laboratories Ltd, Sandoz AG (A subsidiary of Novartis), Novadoz Pharmaceuticals, Accord, Althera Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Salerno Pharma, COVIS PHARMA BV, Medicure Inc., ESPERION THERAPEUTICS, INC., Lupin, Zydus Pharmaceuticals, Inc., AstraZeneca, Concord Biotech, Biocon, Camber Pharmaceuticals, Inc., Ind-Swift Laboratories Ltd., and Teva Pharmaceutical Industries Ltd. among others

Pfizer Inc.

Pfizer Inc. is headquartered in New York, U.S. The company was established in 1849. The company focuses on advance medical innovation and distribution of medicines worldwide. The company has product categories including BioPharma, consumer healthcare, Lipitor in which the market focused category is Lipitor products.

The company is engaged in continuous development of various drugs. For instance,

  • In March 2022, Pfizer Inc. completed acquisition of Arena Pharmaceuticals. Pfizer Inc. (NYSE: PFE) announced the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. This has helped company to expand its business

The company has wide presence across North America, Europe, Middle East and Africa and Asia-Pacific.

AstraZeneca

AstraZeneca is headquartered in Cambridge, U.K., and was founded in 1999. The company focuses on launching new medicines in different disease areas. The company is dealing in medicines as a main focused category.

The company is engaged in continuous development of various drugs. For instance,

  • In July 2021, BYDUREON BCise (exenatide extended-release) approved in the US for the treatment of type 2 diabetes in pediatric patients ages 10 years and older.  AstraZeneca’s BYDUREON BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); to improve glycemic control in pediatric patients (10 to 17 years) as an adjunct to diet and exercise. This has helped company to improve its product portfolio

The company has wide presence across North America, South America, Europe, Middle East and Africa and Asia-Pacific.

U.S. Statin Market

Kowa Pharmaceuticals America Inc.

Kowa Pharmaceuticals America Inc. has its headquarters in Aichi, Japan was founded in 1894. The company focuses on public health and enhancement of developing new products. This company has product categories including health and medical, hospitality, foods in which the market focused category is health and medical.

The company has wide presence across North America, Europe, Middle East and Africa.